Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis
- PMID: 30902670
- DOI: 10.1016/S2468-1253(19)30039-1
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. Asia is a large, heterogeneous area with substantial variation in socioeconomic status and prevalence of obesity. We estimated the prevalence, incidence, and outcomes of NAFLD in the Asian population to assist stakeholders in understanding NAFLD disease burden.
Methods: We searched PubMed, EMBASE, and the Cochrane Library from database inception to Jan 17, 2019, for studies reporting NAFLD prevalence, incidence, or outcome in Asia. We included only cross-sectional and longitudinal observational studies of patients with NAFLD diagnosed by imaging, serum-based indices, or liver biopsy. Studies that included patients with overlapping liver disease or that did not screen for excess alcohol consumption were excluded. Two investigators independently screened and extracted data. The main outcomes were pooled NAFLD prevalence, incidence, and hepatocellular carcinoma incidence and overall mortality in patients with NAFLD. Summary estimates were calculated using a random-effects model. This study is registered with PROSPERO, number CRD42018088468.
Findings: Of 4995 records identified, 237 studies (13 044 518 participants) were included for analysis. The overall prevalence of NAFLD regardless of diagnostic method was 29·62% (95% CI 28·13-31·15). NAFLD prevalence increased significantly over time (25·28% [22·42-28·37] between 1999 and 2005, 28·46% [26·70-30·29] between 2006 and 2011, and 33·90% [31·74-36·12] between 2012 and 2017; p<0·0001). The pooled annual NAFLD incidence rate was 50·9 cases per 1000 person-years (95% CI 44·8-57·4). In patients with NAFLD, the annual incidence of hepatocellular carcinoma was 1·8 cases per 1000 person-years (0·8-3·1) and overall mortality rate was 5·3 deaths per 1000 person-years (1·5-11·4).
Interpretation: NAFLD prevalence in Asia is increasing and is associated with poor outcomes including hepatocellular carcinoma and death. Targeted public health strategies must be developed in Asia to target the drivers of this rising epidemic and its associated complications, especially in high-risk groups, such as older obese men.
Funding: None.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
-
The increasing clinical burden of NAFLD in Asia.Lancet Gastroenterol Hepatol. 2019 May;4(5):333-334. doi: 10.1016/S2468-1253(19)30093-7. Epub 2019 Mar 20. Lancet Gastroenterol Hepatol. 2019. PMID: 30902671 No abstract available.
Similar articles
-
Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.Chin Med J (Engl). 2022 Jul 20;135(14):1682-1691. doi: 10.1097/CM9.0000000000002277. Chin Med J (Engl). 2022. PMID: 36070463 Free PMC article.
-
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.Lancet Oncol. 2022 Apr;23(4):521-530. doi: 10.1016/S1470-2045(22)00078-X. Epub 2022 Mar 4. Lancet Oncol. 2022. PMID: 35255263 Free PMC article.
-
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12. Lancet Gastroenterol Hepatol. 2020. PMID: 32413340
-
Epidemiology of non-alcoholic fatty liver disease in Asia.Indian J Gastroenterol. 2020 Feb;39(1):1-8. doi: 10.1007/s12664-020-01018-x. Epub 2020 Mar 9. Indian J Gastroenterol. 2020. PMID: 32152903 Review.
-
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22. Hepatology. 2016. PMID: 26707365 Review.
Cited by
-
Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis.World J Pediatr. 2024 Jun;20(6):569-580. doi: 10.1007/s12519-024-00814-1. Epub 2024 May 21. World J Pediatr. 2024. PMID: 38771552 Review.
-
Selenium intake in relation to all-cause and cardiovascular mortality in individuals with nonalcoholic fatty liver disease: A nationwide study in nutrition.PLoS One. 2024 May 20;19(5):e0303140. doi: 10.1371/journal.pone.0303140. eCollection 2024. PLoS One. 2024. PMID: 38768120 Free PMC article.
-
Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review.Front Pharmacol. 2024 Apr 17;15:1381712. doi: 10.3389/fphar.2024.1381712. eCollection 2024. Front Pharmacol. 2024. PMID: 38694920 Free PMC article. Review.
-
Metabolic dysfunction-associated steatotic liver disease: A silent pandemic.World J Hepatol. 2024 Apr 27;16(4):511-516. doi: 10.4254/wjh.v16.i4.511. World J Hepatol. 2024. PMID: 38689742 Free PMC article.
-
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.Nutrients. 2024 Mar 22;16(7):920. doi: 10.3390/nu16070920. Nutrients. 2024. PMID: 38612954 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical